首页 > 最新文献

Revue medicale de Liege最新文献

英文 中文
[Right heart catheterization : Technique, interpretation, and indications]. [右心导管:技术、解释和适应症]。
Pub Date : 2025-11-01
Quentin Maloir, Gilles Parzibut, Cedric Davidsen, Patrizio Lancellotti, Julien Guiot, Bernard Lambermont

Despite the widespread use of non-invasive imaging modalities, right heart catheterization remains the gold standard for the hemodynamic assessment of various cardiopulmonary disorders. A Swan-Ganz catheter allows the direct measurement of venous, intracardiac, and pulmonary arterial pressures, as well as cardiac output. Its execution and interpretation require technical precision, given the numerous potential sources of error. This review provides an overview of best practices, common pitfalls, and current clinical indications for right heart catheterization.

尽管非侵入性成像方式的广泛使用,右心导管仍然是各种心肺疾病血液动力学评估的金标准。Swan-Ganz导管可以直接测量静脉、心内和肺动脉压以及心输出量。它的执行和解释需要技术上的精确,因为有许多潜在的错误来源。本文综述了右心导管置入术的最佳实践、常见缺陷和当前临床适应症。
{"title":"[Right heart catheterization : Technique, interpretation, and indications].","authors":"Quentin Maloir, Gilles Parzibut, Cedric Davidsen, Patrizio Lancellotti, Julien Guiot, Bernard Lambermont","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite the widespread use of non-invasive imaging modalities, right heart catheterization remains the gold standard for the hemodynamic assessment of various cardiopulmonary disorders. A Swan-Ganz catheter allows the direct measurement of venous, intracardiac, and pulmonary arterial pressures, as well as cardiac output. Its execution and interpretation require technical precision, given the numerous potential sources of error. This review provides an overview of best practices, common pitfalls, and current clinical indications for right heart catheterization.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 11","pages":"692-702"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Imaging of acute pyelonephritis : diagnostic benefits and prescribing habits]. 急性肾盂肾炎的影像学:诊断益处和处方习惯。
Pub Date : 2025-11-01
Romain Gillard, Flavien Grandjean, Charles Deflandre, Martin Moïse, Paul Meunier, Damien Vannespenne

Acute pyelonephritis is a potentially serious kidney infection that mainly affects women, children and the elderly. It may or may not be symptomatic (fever, pain, urinary disorders), and is most often caused by Escherichia Coli. Its incidence and cost are increasing, particularly in connection with the overuse of imaging. In 2018, clinical criteria were introduced to help identify cases requiring urgent imaging. A retrospective study was carried out at Liège University Hospital to analyse the reliability of these criteria for diagnosing complicated pyelonephritis (abscess or upper urinary tract obstruction). At the same time, prescribing practices were assessed.

急性肾盂肾炎是一种潜在的严重肾脏感染,主要影响妇女、儿童和老年人。它可能有症状,也可能没有症状(发烧、疼痛、泌尿系统紊乱),通常是由大肠杆菌引起的。其发病率和费用正在增加,特别是与过度使用成像有关。2018年,引入了临床标准,以帮助确定需要紧急成像的病例。一项回顾性研究在lige大学医院进行,分析这些诊断标准在诊断复杂性肾盂肾炎(脓肿或上尿路梗阻)中的可靠性。同时,对处方做法进行了评估。
{"title":"[Imaging of acute pyelonephritis : diagnostic benefits and prescribing habits].","authors":"Romain Gillard, Flavien Grandjean, Charles Deflandre, Martin Moïse, Paul Meunier, Damien Vannespenne","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acute pyelonephritis is a potentially serious kidney infection that mainly affects women, children and the elderly. It may or may not be symptomatic (fever, pain, urinary disorders), and is most often caused by Escherichia Coli. Its incidence and cost are increasing, particularly in connection with the overuse of imaging. In 2018, clinical criteria were introduced to help identify cases requiring urgent imaging. A retrospective study was carried out at Liège University Hospital to analyse the reliability of these criteria for diagnosing complicated pyelonephritis (abscess or upper urinary tract obstruction). At the same time, prescribing practices were assessed.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 11","pages":"717-722"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Early management of vitreous hemorrhage : clinical experience of the University Hospital of Liege]. 【列日大学医院玻璃体出血的早期处理】。
Pub Date : 2025-11-01
Natacha Rakic, Françoise Van Cauwenberge, Anouk Georges, Jean-Marie Rakic

Hemorrhages occurring in the vitreous body have multiple etiologies. They cause an immediate and severe loss of visual acuity and sometimes require urgent surgical management by vitrectomy. We report in a retrospective series the clinical data of 76 patients treated at the University Hospital of Liège, highlighting the high incidence of retinal tears caused by posterior detachment of the vitreous body, the predominance of proliferative diabetic retinopathy in young patients, and that of age-related macular degeneration in older patients. Surgical intervention allows a very significant and fast improvement in visual acuity while avoiding the natural history of retinal tears which, in a hemorrhagic context, lead to retinal detachment with a very bad prognosis.

玻璃体出血有多种病因。它们会立即导致严重的视力丧失,有时需要通过玻璃体切除术进行紧急手术治疗。我们回顾性报道了76例在li奇大学医院接受治疗的患者的临床资料,强调了玻璃体后脱离引起的视网膜撕裂的高发性,年轻患者中增殖性糖尿病视网膜病变的优势,以及老年患者中年龄相关性黄斑变性的优势。手术干预可以非常显著和快速地改善视力,同时避免视网膜撕裂的自然历史,在出血的情况下,导致视网膜脱离,预后非常差。
{"title":"[Early management of vitreous hemorrhage : clinical experience of the University Hospital of Liege].","authors":"Natacha Rakic, Françoise Van Cauwenberge, Anouk Georges, Jean-Marie Rakic","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hemorrhages occurring in the vitreous body have multiple etiologies. They cause an immediate and severe loss of visual acuity and sometimes require urgent surgical management by vitrectomy. We report in a retrospective series the clinical data of 76 patients treated at the University Hospital of Liège, highlighting the high incidence of retinal tears caused by posterior detachment of the vitreous body, the predominance of proliferative diabetic retinopathy in young patients, and that of age-related macular degeneration in older patients. Surgical intervention allows a very significant and fast improvement in visual acuity while avoiding the natural history of retinal tears which, in a hemorrhagic context, lead to retinal detachment with a very bad prognosis.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 11","pages":"703-707"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New paradigm in the management of type 2 diabetes]. [2型糖尿病管理的新范例]。
Pub Date : 2025-11-01
André Scheen

Type 2 diabetes management evolved considerably over the past few decades. The present article summarizes three successive key steps : the glucocentric target, the multirisk approach and the organ protection strategy.

在过去的几十年里,2型糖尿病的管理有了很大的发展。本文总结了三个连续的关键步骤:血糖中心目标,多风险方法和器官保护策略。
{"title":"[New paradigm in the management of type 2 diabetes].","authors":"André Scheen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Type 2 diabetes management evolved considerably over the past few decades. The present article summarizes three successive key steps : the glucocentric target, the multirisk approach and the organ protection strategy.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 11","pages":"689-691"},"PeriodicalIF":0.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Between ethics and practice : thoughts about the clinical management of an infant with trisomy 18 (Edwards syndrome)]. [在伦理与实践之间:对婴儿18三体(爱德华兹综合征)临床处理的思考]。
Pub Date : 2025-10-01
Morgane Jankowski, Caroline Lefèbvre, Nadège Hennuy, Vincent Rigo

Trisomy 18, also known as Edwards syndrome, is the second most common autosomal trisomy. The phenotype includes dysmorphia, congenital malformations and severe neurological impairment. The most common malformation is congenital heart disease. With a median survival of 2 to 14.5 days, trisomy 18 has been historically considered as lethal and care has long been palliative. This approach was proposed to a little girl with postnatal diagnosis. Initially, the child's parents disagreed with the management strategy. After further discussions, the parents agreed on a therapeutic approach based on comfort care. Intensive care is, however, offered in selected patients in other countries. Multiple studies have recently shown that measures such as cardiac repair increase survival. Impact on quality of life remains, however, highly uncertain. The therapeutic orientation for these children remains the subject of ethical dilemma. A multitude of arguments are developed around the four fundamental principles of bioethics: autonomy, beneficence, nonmaleficence, and justice. Not only the choice of care (interventional or palliative) but also the person responsible for this decision are controversial.

18三体,也被称为爱德华兹综合征,是第二常见的常染色体三体。其表型包括畸形、先天性畸形和严重的神经损伤。最常见的畸形是先天性心脏病。18三体的中位生存期为2至14.5天,历史上一直被认为是致命的,长期以来的治疗都是姑息性的。这种方法是提出了一个小女孩产后诊断。起初,孩子的父母不同意这种管理策略。经过进一步的讨论,父母同意采用一种基于舒适护理的治疗方法。然而,在其他国家,对选定的病人提供重症监护。最近多项研究表明,心脏修复等措施可以提高生存率。然而,对生活质量的影响仍然高度不确定。这些儿童的治疗取向仍然是伦理困境的主题。围绕生命伦理学的四个基本原则,出现了大量的争论:自主、仁慈、无害和正义。不仅是治疗的选择(介入性还是姑息性),而且负责这个决定的人也存在争议。
{"title":"[Between ethics and practice : thoughts about the clinical management of an infant with trisomy 18 (Edwards syndrome)].","authors":"Morgane Jankowski, Caroline Lefèbvre, Nadège Hennuy, Vincent Rigo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Trisomy 18, also known as Edwards syndrome, is the second most common autosomal trisomy. The phenotype includes dysmorphia, congenital malformations and severe neurological impairment. The most common malformation is congenital heart disease. With a median survival of 2 to 14.5 days, trisomy 18 has been historically considered as lethal and care has long been palliative. This approach was proposed to a little girl with postnatal diagnosis. Initially, the child's parents disagreed with the management strategy. After further discussions, the parents agreed on a therapeutic approach based on comfort care. Intensive care is, however, offered in selected patients in other countries. Multiple studies have recently shown that measures such as cardiac repair increase survival. Impact on quality of life remains, however, highly uncertain. The therapeutic orientation for these children remains the subject of ethical dilemma. A multitude of arguments are developed around the four fundamental principles of bioethics: autonomy, beneficence, nonmaleficence, and justice. Not only the choice of care (interventional or palliative) but also the person responsible for this decision are controversial.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"666-670"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications]. [Semaglutide 2.4 mg (Wegovy®)用于治疗伴有体重相关并发症的临床肥胖]。
Pub Date : 2025-10-01
André Scheen, Nathalie Esser, Jenny De Flines, Nicolas Paquot

Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also indicated at a weekly dose up to 2.4 mg for the management of obesity or over-weight with at least one weight-related comorbidity, after failure and in combination with life-style interventions. Its efficacy and tolerance were investigated in the STEP clinical research programme. Gastrointestinal adverse events after initiation of therapy, as with all glucagon-like peptide-1 receptor agonists, requires a progressive titration every 4 weeks from 0.25 mg to 2.4 mg/week. It is the first anti-obesity medication that has shown a significant reduction of major cardiovascular events and all-cause mortality in the large placebo-controlled SELECT trial. Wegovy® is commercialized in Belgium (currently not reimbursed) according to the indications supported by the European Medicines Agency (EMA) both in adults and adolescents suffering from obesity or overweight with at least one weight-related complication, ideally within a holistic multidisciplinary approach.

Semaglutide (Ozempic®),每周皮下注射剂量为1.0 mg,在2型糖尿病管理的国际指南中占有特殊地位。semaglutide以商品名Wegovy®商业化,每周剂量高达2.4 mg,用于治疗失败后至少伴有一种体重相关合并症的肥胖或超重,并与生活方式干预相结合。在STEP临床研究计划中对其疗效和耐受性进行了研究。与所有胰高血糖素样肽-1受体激动剂一样,治疗开始后的胃肠道不良事件需要每4周逐步滴定0.25 mg至2.4 mg/周。这是第一个在大型安慰剂对照SELECT试验中显示出主要心血管事件和全因死亡率显著降低的抗肥胖药物。根据欧洲药品管理局(EMA)支持的适应症,Wegovy®在比利时商业化(目前未报销),适用于患有肥胖或超重且至少有一种体重相关并发症的成人和青少年,理想情况下是在整体多学科方法中。
{"title":"[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].","authors":"André Scheen, Nathalie Esser, Jenny De Flines, Nicolas Paquot","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also indicated at a weekly dose up to 2.4 mg for the management of obesity or over-weight with at least one weight-related comorbidity, after failure and in combination with life-style interventions. Its efficacy and tolerance were investigated in the STEP clinical research programme. Gastrointestinal adverse events after initiation of therapy, as with all glucagon-like peptide-1 receptor agonists, requires a progressive titration every 4 weeks from 0.25 mg to 2.4 mg/week. It is the first anti-obesity medication that has shown a significant reduction of major cardiovascular events and all-cause mortality in the large placebo-controlled SELECT trial. Wegovy® is commercialized in Belgium (currently not reimbursed) according to the indications supported by the European Medicines Agency (EMA) both in adults and adolescents suffering from obesity or overweight with at least one weight-related complication, ideally within a holistic multidisciplinary approach.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"682-688"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Anti-MOG antibody encephalitis mimicking herpes simplex encephalitis]. [抗mog抗体脑炎模拟单纯疱疹脑炎]。
Pub Date : 2025-10-01
Frédéric Hatt, Jean-Marie Jacques

We report the case of an 18-year-old man admitted to the emergency department with suspected herpes simplex encephalitis. He presented with headaches, memory disorders, and a low-grade fever at home, not found in the emergency room. The clinical examination revealed minimal temporal disorientation, contrasting with the cerebral MRI showing bilateral temporo-insular lesions suggestive of herpes simplex encephalitis. Because of ineffective aciclovir treatment and negative HSV-1 PCR in the cerebrospinal fluid, a search for serum anti-MOG antibodies was carried out, confirming autoimmune encephalitis. High-dose corticosteroid treatment allowed progressive neurological improvement. Anti-MOG antibody encephalitis is an autoimmune central nervous system disorder with a broad clinical spectrum. Diagnosis is based on anti-MOG antibody detection and cerebral MRI. First-line treatment is high-dose corticosteroid therapy. This case illustrates the complexity of the differential diagnosis of acute encephalitis and the importance of considering autoimmune etiologies, even in cases with a presentation suggestive of herpes simplex encephalitis. Close collaboration between emergency physicians, neurologists, and immunologists is necessary to optimize patient management.

我们报告的情况下,18岁的男子承认急诊部门怀疑单纯疱疹脑炎。他表现出头痛、记忆障碍和在家中出现的低烧,这些症状在急诊室都没有出现。临床检查显示轻度颞叶定向障碍,与大脑MRI显示提示单纯疱疹脑炎的双侧颞岛病变形成对比。由于阿昔洛韦治疗无效,脑脊液HSV-1 PCR阴性,因此进行了血清抗mog抗体的搜索,确认自身免疫性脑炎。大剂量皮质类固醇治疗可使神经系统渐进式改善。抗mog抗体脑炎是一种具有广泛临床谱系的自身免疫性中枢神经系统疾病。诊断基于抗mog抗体检测和脑MRI。一线治疗是大剂量皮质类固醇治疗。本病例说明了急性脑炎鉴别诊断的复杂性和考虑自身免疫性病因的重要性,即使在有单纯疱疹脑炎表现的病例中也是如此。急诊医生、神经科医生和免疫学家之间的密切合作是优化患者管理的必要条件。
{"title":"[Anti-MOG antibody encephalitis mimicking herpes simplex encephalitis].","authors":"Frédéric Hatt, Jean-Marie Jacques","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report the case of an 18-year-old man admitted to the emergency department with suspected herpes simplex encephalitis. He presented with headaches, memory disorders, and a low-grade fever at home, not found in the emergency room. The clinical examination revealed minimal temporal disorientation, contrasting with the cerebral MRI showing bilateral temporo-insular lesions suggestive of herpes simplex encephalitis. Because of ineffective aciclovir treatment and negative HSV-1 PCR in the cerebrospinal fluid, a search for serum anti-MOG antibodies was carried out, confirming autoimmune encephalitis. High-dose corticosteroid treatment allowed progressive neurological improvement. Anti-MOG antibody encephalitis is an autoimmune central nervous system disorder with a broad clinical spectrum. Diagnosis is based on anti-MOG antibody detection and cerebral MRI. First-line treatment is high-dose corticosteroid therapy. This case illustrates the complexity of the differential diagnosis of acute encephalitis and the importance of considering autoimmune etiologies, even in cases with a presentation suggestive of herpes simplex encephalitis. Close collaboration between emergency physicians, neurologists, and immunologists is necessary to optimize patient management.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"642-644"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cannabis, CBD, THC : therapeutic potential, realities and latest discoveries]. [大麻,CBD, THC:治疗潜力,现实和最新发现]。
Pub Date : 2025-10-01
Vicky Gilles, Didier Wégimont

This article aims to provide an update on the use of CBD in the fields of psychiatry, neurology and pediatrics. It details the pharmacological properties of cannabidiol (CBD), a non-psychoactive molecule of cannabis, and its interaction with various receptors in the nervous system. This article explores its potential therapeutic applications, especially for the treatment of epilepsy, chronic pain, anxiety disorders and neurodegenerative diseases. It also presents the CBD-based medications available in Belgium, the regulatory challenges and the scientific uncertainties surrounding their long-term efficacy and safety. Although CBD shows promise, further studies are needed to validate its clinical use and better understand its side effects and drug interactions.

本文旨在提供CBD在精神病学、神经病学和儿科领域使用的最新情况。它详细介绍了大麻二酚(CBD)的药理学特性,大麻的一种非精神活性分子,以及它与神经系统中各种受体的相互作用。本文探讨了其潜在的治疗应用,特别是在治疗癫痫,慢性疼痛,焦虑症和神经退行性疾病。它还介绍了比利时现有的基于cbd的药物,监管挑战以及围绕其长期疗效和安全性的科学不确定性。虽然CBD显示出希望,但需要进一步的研究来验证其临床应用,并更好地了解其副作用和药物相互作用。
{"title":"[Cannabis, CBD, THC : therapeutic potential, realities and latest discoveries].","authors":"Vicky Gilles, Didier Wégimont","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article aims to provide an update on the use of CBD in the fields of psychiatry, neurology and pediatrics. It details the pharmacological properties of cannabidiol (CBD), a non-psychoactive molecule of cannabis, and its interaction with various receptors in the nervous system. This article explores its potential therapeutic applications, especially for the treatment of epilepsy, chronic pain, anxiety disorders and neurodegenerative diseases. It also presents the CBD-based medications available in Belgium, the regulatory challenges and the scientific uncertainties surrounding their long-term efficacy and safety. Although CBD shows promise, further studies are needed to validate its clinical use and better understand its side effects and drug interactions.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"654-659"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Indications of direct oral anticoagulant rivaroxaban in cardiovascular disease]. 直接口服抗凝药物利伐沙班治疗心血管疾病的适应症
Pub Date : 2025-10-01
André Scheen, Patrizio Lancellotti

Rivaroxaban, an oral direct anticoagulant that is a selective inhibitor of Xa factor, was commercialized in Belgium in 2009 with as unique reimbursed indication the prevention of thromboembolic events before a programmed hip or knee prosthesis. Since that time, both the efficacy and safety of rivaroxaban have been validated in a variety of indications : prevention and treatment of venous thromboembolic disease with or without pulmonary embolism, non valvular atrial fibrillation, symptomatic coronary disease and peripheral arteriopathy. Different presentations are currently available from 2.5 mg to 20 mg to allow the practitioner adjust the dosage of rivaroxaban to the specific indication (for instance, in patents with symptomatic atheromatous cardiovascular disease, 2 x 2.5 mg/day in combination with a antiplatelet agent).

利伐沙班(Rivaroxaban)是一种口服直接抗凝剂,是Xa因子的选择性抑制剂,于2009年在比利时商业化,作为一种独特的报销适应症,用于预防程序化髋关节或膝关节假体前的血栓栓塞事件。从那时起,利伐沙班的有效性和安全性在多种适应症中得到了验证:预防和治疗伴有或不伴有肺栓塞的静脉血栓栓塞性疾病、非瓣膜性心房颤动、症状性冠状动脉疾病和外周动脉病变。目前可提供从2.5 mg到20mg的不同剂量,以允许医生根据特定适应症调整利伐沙班的剂量(例如,在有症状的动脉粥样硬化性心血管疾病的患者中,2 × 2.5 mg/天与抗血小板药物联合使用)。
{"title":"[Indications of direct oral anticoagulant rivaroxaban in cardiovascular disease].","authors":"André Scheen, Patrizio Lancellotti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Rivaroxaban, an oral direct anticoagulant that is a selective inhibitor of Xa factor, was commercialized in Belgium in 2009 with as unique reimbursed indication the prevention of thromboembolic events before a programmed hip or knee prosthesis. Since that time, both the efficacy and safety of rivaroxaban have been validated in a variety of indications : prevention and treatment of venous thromboembolic disease with or without pulmonary embolism, non valvular atrial fibrillation, symptomatic coronary disease and peripheral arteriopathy. Different presentations are currently available from 2.5 mg to 20 mg to allow the practitioner adjust the dosage of rivaroxaban to the specific indication (for instance, in patents with symptomatic atheromatous cardiovascular disease, 2 x 2.5 mg/day in combination with a antiplatelet agent).</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"660-665"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of ectopic pregnancies: therapeutic options and clinical decision-making criteria]. 异位妊娠的管理:治疗方案和临床决策标准。
Pub Date : 2025-10-01
Dorra El Harran, Maxime Jason

Ectopic pregnancy is a gynecological emergency that can be life-threatening if not diagnosed and treated promptly. This review discusses therapeutic options, comparing medical and surgical management based on clinical and biological data of patients, aiming to guide practitioners in selecting the optimal treatment according to hCG (human chorionic gonadotrophin) levels and patient hemodynamics. Approximately 1-2 % of pregnancies are ectopic, with an associated mortality rate that has decreased in recent decades due to advancements in diagnosis and treatment.

异位妊娠是一种妇科急症,如果不及时诊断和治疗,可能会危及生命。本文根据患者的临床和生物学资料,讨论治疗方案,比较内科和外科治疗方案,旨在指导医生根据hCG(人绒毛膜促性腺激素)水平和患者血流动力学选择最佳治疗方案。大约1- 2%的妊娠是异位妊娠,近几十年来,由于诊断和治疗的进步,其相关死亡率有所下降。
{"title":"[Management of ectopic pregnancies: therapeutic options and clinical decision-making criteria].","authors":"Dorra El Harran, Maxime Jason","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ectopic pregnancy is a gynecological emergency that can be life-threatening if not diagnosed and treated promptly. This review discusses therapeutic options, comparing medical and surgical management based on clinical and biological data of patients, aiming to guide practitioners in selecting the optimal treatment according to hCG (human chorionic gonadotrophin) levels and patient hemodynamics. Approximately 1-2 % of pregnancies are ectopic, with an associated mortality rate that has decreased in recent decades due to advancements in diagnosis and treatment.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 10","pages":"636-641"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revue medicale de Liege
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1